Alto Neuroscience Target of Unusually High Options Trading (NYSE:ANRO)

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) was the target of some unusual options trading on Wednesday. Investors bought 2,129 call options on the stock. This is an increase of approximately 21% compared to the average volume of 1,755 call options.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently modified their holdings of the stock. Federated Hermes Inc. grew its position in shares of Alto Neuroscience by 33.3% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock worth $128,000 after buying an additional 3,000 shares during the period. Bowie Capital Management LLC acquired a new position in shares of Alto Neuroscience during the 2nd quarter worth about $462,000. TD Asset Management Inc acquired a new position in shares of Alto Neuroscience during the 2nd quarter worth about $928,000. Rhumbline Advisers acquired a new position in shares of Alto Neuroscience during the 2nd quarter worth about $113,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Alto Neuroscience during the 2nd quarter worth about $252,000.

Wall Street Analysts Forecast Growth

ANRO has been the subject of a number of research analyst reports. Wedbush cut Alto Neuroscience from an "outperform" rating to a "neutral" rating and cut their price target for the company from $29.00 to $4.00 in a report on Wednesday. William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Rodman & Renshaw cut Alto Neuroscience from a "buy" rating to a "neutral" rating in a report on Wednesday. Finally, Robert W. Baird lowered their price objective on Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating for the company in a research report on Wednesday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Alto Neuroscience presently has an average rating of "Moderate Buy" and an average price target of $24.40.

Alto Neuroscience Trading Down 70.0 %

ANRO stock traded down $10.17 during midday trading on Wednesday, reaching $4.36. The stock had a trading volume of 16,254,234 shares, compared to its average volume of 335,567. The business has a fifty day simple moving average of $12.22 and a two-hundred day simple moving average of $12.48. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.85 and a quick ratio of 19.85. Alto Neuroscience has a twelve month low of $4.26 and a twelve month high of $24.00.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.67) by $0.07. As a group, sell-side analysts predict that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.